Salvage use of tofacitinib in sarcoidosis patient with refractory multiorgan involvement

Main Article Content

Inês Farinha
Pedro Gonçalo Ferreira

Keywords

Sarcoidosis, Refractory disease, Tofacitinib

Abstract 67 | PDF Downloads 49

References

1. Goll GL, Kvien TK. Generic Tofacitinib-A More Affordable JAK Inhibitor. Mayo Clin Proc. 2024;99(1):4-6.
2. Bilgin B, Bilgin MK, Erol S, Celik G, Ozdemir Kumbasar O. Prognosis of sarcoidosis and factors affecting prognosis. Sarcoidosis Vasc Diffuse Lung Dis. 2023;40(4):e2023054.
3. Friedman MA, Le B, Stevens J, et al. Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study. Lung. 2021;199(2):147-53.
4. Damsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of Multiorgan Sarcoidosis With Tofacitinib. ACR Open Rheumatol. 2020;2(2):106-9.
5. Kerkemeyer KL, Meah N, Sinclair RD. Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series. J Am Acad Dermatol. 2021;84(2):581-3.
6. Liu B, Yin H, Yang S, Lu L. Janus kinase inhibitor treatment improved both subcutaneous and pulmonary sarcoidosis in a patient with glaucoma. Clin Exp Dermatol. 2022;47(10):1868-70.
7. Toriola SL, Satnarine T, Zohara Z, et al. Recent Clinical Studies on the Effects of Tumor Necrosis Factor-Alpha (TNF-α) and Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) Antibody Therapies in Refractory Cutaneous Sarcoidosis: A Systematic Review. Cureus. 2023;15(9):e44901.
8. Xu Q, Huang ZS, Liu QP, Wei JC. Tofacitinib for sarcoidosis, a new potential treatment. Int J Rheum Dis. 2022;25(11):1217-9.
9. Damsky W, Wang A, Kim DJ, et al. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nat Commun. 2022;13(1):3140.